Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company

Needham & Company raised its price target on Akebia Therapeutics (NASDAQ: AKBA) to $21.00 (from $18.00) while maintaining a Buy rating. Akebia is licensing vadadustat distribution rights to Vifor Pharma for exclusive sale to Fresnius Medical Care. The deal will rapidly give vadadustat access to 40% of the dialysis market assuming its approval and inclusion in the reimbursement bundle.

Analyst Chad Messer sees the deal as a positive for the future commercial opportunity and for the immediate funding needs at Akebia as Vifor is making a $50M equity investment in Akebia at a premium to its trailing stock price.

You May Also Be Interested In

• Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR18 at JPMorgan
• Adobe (ADBE) PT Lowered to $379 at Bernstein SocGen Amid 'Increased Uncertainties'
• Datadog (DDOG) PT Raised to $260 at BMO Capital